药物性肝损伤发生机制的研究进展  

Progress in the Study of the Mechanism of Drug-induced Liver Injury

作　　者：马璟婷 宋沧桑[1,2] 李兴德 毛盼盼[1] 马雪娇 MA Jing-ting;SONG Cang-sang;LI Xing-de;MAO Pan-pan;MA Xue-jiao(Department of Pharmacy,the First people′s Hospital of Kunming,Yunnan Kunming 650000,China;College of Pharmacy,Dali University,Yunnan Dali 671000,China)

机构地区：[1]昆明市第一人民医院药学部,云南昆明650000 [2]大理大学药学院,云南大理671000

出　　处：《中国药物评价》2024年第2期132-135,共4页Chinese Journal of Drug Evaluation

基　　金：云南省临床药学中心建设项目;云南省卫生健康委员会医学领军人才培养项目(L-2018012);昆明市医学科技领军人才培养项目(2023-SW-04)

摘　　要：药物性肝损伤(drug induced liver injury,DILI)是全球范围内常见的药品不良反应,也是临床实践中一直尚未解决的问题,其发病率和致死率逐年升高。DILI的发生可能是多种因素共同作用的结果,至今尚未完全阐明。本研究通过查阅相关文献对药物性肝损伤机制的研究进展进行综述,以期为其临床科学预防、诊断和治疗提供参考。Drug induced liver injury(DILI)is a common adverse drug reaction worldwide and an unresolved problem in clinical practice,with its incidence and lethality increasing year by year.The occurrence of DILI may be the result of a combination of factors,which have not been fully elucidated so far.In this study,we reviewed the research progress on the mechanism of drug-induced liver injury by reviewing the related literature,aiming to provide a reference for its prevention,diagnosis,and treatment in clinical science.

关 键 词：药物性肝损伤 发生机制 免疫反应 线粒体损伤 基因多态性 胆汁酸稳态失衡 自噬 炎症应激 

分 类 号：R575[医药卫生—消化系统]